biostudies-literatureUnknown13Liu CCG258 is the dominant carbapenemase-producing <i>Klebsiella pneumoniae</i> clone worldwide and treatment of infections caused by this clone relies largely on the last-line antibiotics, colistin, and tigecycline. However, the emergence and global dissemination of <i>mcr</i> and <i>tmexCD1</i>-<i>toprJ1</i> genes have significantly compromised their clinical applications. CG258 <i>K. pneumoniae</i> carrying both <i>mcr</i> and <i>tmexCD1</i>-<i>toprJ1</i> have not been reported. A colistin-resistant strain T698-1 belonging to ST1326, a member of CG258, was isolated from the intestinal sample of a patient and characterized by the antimicrobial susceptibility testing, conjugation assay, WGS and bioinformatics analysis. It was resistant to colistin, tetracycline, aminoglycoside, fluoroqinolone,Frontiers in microbiology800993https://www.ebi.ac.uk/biostudies/studies/S-EPMC8969419biostudies-literatureEmergence of an ST1326 (CG258) Multi-Drug Resistant <i>Klebsiella pneumoniae</i> Co-harboring <i>mcr-8.2</i>, ESBL Genes, and the Resistance-Nodulation-Division Efflux Pump Gene Cluster <i>tmexCD1-toprJ1</i> in China.PMC8969419Fang YLu JChen GLiu CHuang LDong NZeng YSang ZZhang RWu YfalseEmergence of an ST1326 (CG258) Multi-Drug Resistant <i>Klebsiella pneumoniae</i> Co-harboring <i>mcr-8.2</i>, ESBL Genes, and the Resistance-Nodulation-Division Efflux Pump Gene Cluster <i>tmexCD1-toprJ1</i> in China.CG258 is the dominant carbapenemase-producing <i>Klebsiella pneumoniae</i> clone worldwide and treatment of infections caused by this clone relies largely on the last-line antibiotics, colistin, and tigecycline. However, the emergence and global dissemination of <i>mcr</i> and <i>tmexCD1</i>-<i>toprJ1</i> genes have significantly compromised their clinical applications. CG258 <i>K. pneumoniae</i> carrying both <i>mcr</i> and <i>tmexCD1</i>-<i>toprJ1</i> have not been reported. A colistin-resistant strain T698-1 belonging to ST1326, a member of CG258, was isolated from the intestinal sample of a patient and characterized by the antimicrobial susceptibility testing, conjugation assay, WGS and bioinformatics analysis. It was resistant to colistin, tetracycline, aminoglycoside, fluoroqinolone,2022-01-01T00:00:00Z20222025-04-04T12:44:57.216Z2025-04-04T12:44:57.216ZS-EPMC89694193536944110.3389/fmicb.2022.800993